- Home
- PHVS vs XOMAP Comparison
PHVS vs XOMAP Comparison
Compare PHVS & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHVS
- XOMAP
- Stock Information
- Founded
- PHVS 2015
- XOMAP N/A
- Country
- PHVS Netherlands
- XOMAP United States
- Employees
- PHVS N/A
- XOMAP 13
- Industry
- PHVS Biotechnology: Pharmaceutical Preparations
- XOMAP Biotechnology: Pharmaceutical Preparations
- Sector
- PHVS Health Care
- XOMAP Health Care
- Exchange
- PHVS Nasdaq
- XOMAP Nasdaq
- Market Cap
- PHVS N/A
- XOMAP N/A
- IPO Year
- PHVS 2021
- XOMAP N/A
- Fundamental
- Price
- PHVS $18.00
- XOMAP $25.75
- Analyst Decision
- PHVS Strong Buy
- XOMAP
- Analyst Count
- PHVS 5
- XOMAP 0
- Target Price
- PHVS $40.40
- XOMAP N/A
- AVG Volume (30 Days)
- PHVS 84.1K
- XOMAP N/A
- Earning Date
- PHVS 04-07-2025
- XOMAP N/A
- Dividend Yield
- PHVS N/A
- XOMAP N/A
- EPS Growth
- PHVS N/A
- XOMAP N/A
- EPS
- PHVS N/A
- XOMAP N/A
- Revenue
- PHVS N/A
- XOMAP N/A
- Revenue This Year
- PHVS N/A
- XOMAP N/A
- Revenue Next Year
- PHVS N/A
- XOMAP N/A
- P/E Ratio
- PHVS N/A
- XOMAP N/A
- Revenue Growth
- PHVS N/A
- XOMAP N/A
- 52 Week Low
- PHVS $11.51
- XOMAP N/A
- 52 Week High
- PHVS $25.50
- XOMAP N/A
- Technical
- Relative Strength Index (RSI)
- PHVS 63.51
- XOMAP 55.16
- Support Level
- PHVS $16.68
- XOMAP $25.84
- Resistance Level
- PHVS $18.07
- XOMAP $26.08
- Average True Range (ATR)
- PHVS 0.93
- XOMAP 0.27
- MACD
- PHVS 0.50
- XOMAP 0.03
- Stochastic Oscillator
- PHVS 81.65
- XOMAP 86.82
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.